Abstract
Reports of malignant pericardial effusion due to adenocarcinoma of the prostate are few and describe only patients with hormone-naive disease. We report a case of malignant pleural and pericardial effusions due to metastatic hormone-refractory prostate cancer. Despite presenting with pericardial tamponade, this patient was successfully treated with pericardiocentesis and intrapericardial methylprednisolone and cisplatin, followed by a course of intravenous docetaxel. The patient was alive and free of disease-related symptoms nearly 2 years later. This case suggests that patients with pericardial tamponade due to hormone-refractory prostate cancer do not have a uniformly dismal prognosis and should be considered for aggressive treatment.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / complications*
-
Adenocarcinoma / drug therapy
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cardiac Tamponade / drug therapy
-
Cardiac Tamponade / etiology
-
Cardiac Tamponade / therapy*
-
Cisplatin / administration & dosage
-
Combined Modality Therapy
-
Docetaxel
-
Humans
-
Male
-
Methylprednisolone / administration & dosage
-
Middle Aged
-
Paclitaxel / administration & dosage
-
Paclitaxel / analogs & derivatives*
-
Pericardial Effusion / drug therapy
-
Pericardial Effusion / etiology
-
Pericardial Effusion / therapy*
-
Pericardiocentesis
-
Pleural Effusion / drug therapy
-
Pleural Effusion / etiology
-
Pleural Effusion / therapy*
-
Prostatic Neoplasms / complications*
-
Prostatic Neoplasms / drug therapy
-
Taxoids*
Substances
-
Taxoids
-
Docetaxel
-
Paclitaxel
-
Cisplatin
-
Methylprednisolone